Argenica Therapeutics Limited

ASX:AGN Stock Report

Market Cap: AU$71.8m

Argenica Therapeutics Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Argenica Therapeutics.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth26.3%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Jan 12
Companies Like Argenica Therapeutics (ASX:AGN) Are In A Position To Invest In Growth

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Jul 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

Apr 20
Argenica Therapeutics (ASX:AGN) Is In A Strong Position To Grow Its Business

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Nov 30
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Aug 12
Argenica Therapeutics (ASX:AGN) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Apr 29
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

Dec 30
Here's Why We're Not Too Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Situation

We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

Sep 16
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Argenica Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

ASX:AGN - Analysts future estimates and past financials data (AUD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20233-5-4-4N/A
9/30/20232-5-3-3N/A
6/30/20232-5-3-3N/A
3/31/20232-4-3-3N/A
12/31/20221-4-2-2N/A
9/30/20221-4-3-3N/A
6/30/20220-4-3-3N/A
3/31/20220-3-3-3N/A
12/31/20210-3-3-3N/A
9/30/20210-2-2-2N/A
6/30/20210-1-1-1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if AGN's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if AGN's earnings are forecast to grow faster than the Australian market

High Growth Earnings: Insufficient data to determine if AGN's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if AGN's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if AGN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if AGN's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.